Development of a COVID-19 Vaccine

支持候选产品的高级开发，用于故意释放或应对由NIAID A、B和C类优先病原体或新发传染病引起的自然发生的传染病暴发。该合同可能支持单个疫苗成分的配方和生产，以及稳定性测试、动物模型的非临床免疫原性和有效性测试、IND启用GLP毒理学、IND提交以及临床安全性和有效性评估。

To support the advanced development of candidate products for use following the intentional release of or in response to naturally occurring outbreaks of infectious diseases caused by NIAID Category A, B, and C Priority Pathogens or emerging infectious diseases. This contract may support formulation and manufacture of the individual vaccine components, as well as stability testing, nonclinical immunogenicity and efficacy testing in animal models, IND enabling GLP toxicology, submission of an IND and clinical safety and efficacy evaluation.